OnCo
technologiesTechnologyStandard of care

Sterile fill-finish and lyophilisation

Sterile fill-finish is putting the finished drug into vials under sterile conditions. It is a frequent cause of shortages when capacity is tight.

Fill-finish capacity for biologics, ADCs, and radiopharmaceutical kits is concentrated (Catalent, Vetter, Baxter BioPharma Solutions, Thermo Fisher, Lonza, Samsung Biologics); lyophilisation is common for ADCs and mRNA products. Shortages of cisplatin and carboplatin in 2023 traced to a single sterile injectables plant (Intas/Accord) failing inspection, exposing the fragility of generic oncology supply.

Generic schematic · not to scale · placeholder for the adcs front
Antibody (Fc) · Payload on cleavable linker (DAR 8) · Antigen-binding arm

How it works

Fill-finish relies on aseptic filling in isolators, lyophilisation cycles tuned to product stability, and 100% container-closure integrity inspection.

Strengths
  • Established GMP
Limitations
  • Concentrated capacity
  • Generic injectable shortages
  • Long qualification times

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Sterile fill-finish and lyophilisation" OR ABSTRACT:"Sterile fill-finish and lyophilisation") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sterile fill-finish and lyophilisation, not a curated reading list.

Connected

11top